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The main objective of this preliminary study was to further clarify the association between
testosterone (T) levels and depression by investigating symptom-based depression
subtypes in a sample of 64 men. The data were taken from the ZInEP epidemiology
survey. Gonadal hormones of a melancholic (n=25) and an atypical (n=14) depression
subtype, derived from latent class analysis, were compared with those of healthy controls
(n=18). Serum T was assayed using an enzyme-linked immunosorbent assay procedure.
Analysis of variance, analysis of covariance, non-parametrical tests, and generalized linear
regression models were performed to examine group differences. The atypical depressive
subtype showed significantly lower T levels compared with the melancholic depressives.
While accumulative evidence indicates that, beyond psychosocial characteristics, the
melancholic and atypical depressive subtypes are also distinguishable by biological
correlates, the current study expanded this knowledge to include gonadal hormones.
Further longitudinal research is warranted to disclose causality by linking the multiple
processes in pathogenesis of depression.
Keywords: testosterone, depression, subtypes, epidemiology, cross-sectional study
Introduction
Apart from its gonadal functions, testosterone (T) has a significant influence on the human
brain through various neurobiological processes (1–3). In men, associations between T levels and
depressive symptoms have been proposed (3, 4). Such neuroendocrine dysfunctions may play an
important role in the pathogenesis of major depressive disorder (MDD) (5). In particular, low T
levels (hypogonadism) have been associated with depression (4, 6–8), and there is evidence that
T secretion is impaired during depressed mood (9, 10). However, this association has not been
observed consistently and some studies did not find any relationship betweenT levels and depression
(11, 12). These inconsistent findings could be explained by the heterogeneity of the construct of
MDD (13) or difficulties concerning the measurement of salivary T versus that of serum T (14).
Moreover, many findings stem from studies involving exogenous T administration, whereas studies
looking at the effects of endogenous T are lacking (15). In sum, there appears to be insufficient
evidence to conclude that low T levels are routinely involved in the pathogenesis of MDD in
men (15).
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However, a growing body of evidence suggests that theremay be
subpopulations ofmen vulnerable to depression inwhich hypogo-
nadism is a contributing factor (16). Some studies showed that low
T levels were specifically associated with subthreshold depressive
disorders, such as dysthymia or minor depression (15, 17–20).
Other studies demonstrated that hypogonadism was related to
the specific depressive symptoms of dysphoria, irritability, fatigue,
lethargy, decreased libido, and decreased concentration (6, 15).
This symptom cluster has also been conceptualized as “irritable
male syndrome,” occurring in adult male mammals following
withdrawal of T (21).
Meanwhile, some investigations have drawn attention to non-
linear associations between total T levels and depressive symp-
toms, with increased depression rates at both the lowest and the
highest extremes of T levels (15, 22). Furthermore, exogenous T
administration has not only been related to depression but also
to hypomania and even mania (23–28). Despite these suggestive
findings, to date, the associations between dysregulated endoge-
nous T levels and affective symptoms remain fairly unclear (15).
Apart from the findings with regard to the hypothalamic–
pituitary–gonadal (HPG) axis, previous studies have investigated
associations between atypical and melancholic (typical)
depression and the hypothalamic–pituitary–adrenal axis (HPA),
the inflammatory response system and metabolic abnormalities
(29, 30). Melancholic depression has been characterized by hyper-
cortisolemia (HPA axis), whereas atypical depression has been
associated with the opposite imbalance, namely hypocortisolemia
(31). The HPA axis also interacts with gonadal hormones (32, 33)
and Sigurdsson et al. (34) found a positive correlation between
evening cortisol and evening T levels. Therefore, one might
hypothesize that melancholic depression is associated with high T
levels and atypical depression shows the opposite, that is to say low
T levels. Moreover, T levels are negatively correlated with the body
mass index (BMI) (35), and atypical depression is characterized
by a higher BMI (36), further supporting the hypothesis.
Consequently, the melancholic and atypical depression subtypes
might not only be distinguishable by differing activity of the HPA
axis but by that of the HPG axis as well.
In view of the inconsistency of the findings summarized above,
this preliminary study set out to examine the differences in serum
T levels in symptom-based depression subtypes, compared with
healthy controls. The classification of these depression subtypes
was based on a previous latent class analysis, derived from the
depressive symptom profiles of an epidemiological sample of
males (37). The purpose of this paper is to provide an alternative
approach to the area of research by analyzing T levels in empir-
ically derived depression subgroups. Based on previous findings
with regard to T and depression and by drawing analogies to the
HPA axis, we expected differing T levels between these depressive
subgroups, with higher T levels for the melancholic depression
subgroup and lower T levels for the high BMI associated, atypical
depression subgroup.
Materials and Methods
Study Design and Sampling
Data from the epidemiology survey of theZurich Program for Sus-
tainableDevelopment ofMentalHealth Services (ZInEP;German:
FIGURE 1 | The sampling procedure of the ZInEP epidemiology survey.
Zürcher Impulsprogramm zur nachhaltigen Entwicklung der Psy-
chiatrie) were used. The epidemiology survey was conducted in
order to collect comprehensive data about mental health in the
general population of adults in the canton of Zurich. The sur-
vey was methodologically designed as a cross-sectional sequel
to the prospective Zurich cohort study (38), e.g., the instru-
ments and the age structure were parallelized. It consisted of
three components: (a) a brief telephone screening (n= 9829), (b)
a structured face-to-face-interview supplemented by self-report
questionnaires (n= 1500), and (c) a laboratory day followed by
a longitudinal survey (n= 227) (see Figure 1). The survey was
carried out between August 2010 and September 2012. In the
following, only the laboratory day (c) providing the biological data
will be elucidated. For more details with regard to (a) and (b), see
Ajdacic-Gross et al. (39).
For the laboratory day, a subsample of 227 subjects was selected
from the face-to-face sample (n= 1500). Sample construction was
based on the outcomes of two psychoticism scales [schizophrenia
nuclear symptoms scale (SNS) and schizotypal signs scale (STS)
(40)], which were included in the screening interview, as follows:
highest quintile on both scales; highest quintile on the SNS, any
quintile on the STS; highest quintile on the STS, any quintile on
the SNS; controls with a low overall global severity index (GSI)
(41); and no use of professional help. The participation rate was
53.8% and depended mainly on the ease of acquiring the subjects
for the time-consuming set of tests performed during a day in the
sociophysiological laboratory of the Zurich University Hospital
of Psychiatry. The participants were interviewed, provided saliva,
blood, and urine samples, completed computer based tests, and
underwent several tests involving electroencephalographic (EEG)
and near infrared spectroscopy (NIRS) measurement. All tests
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were carried out by a biologist and three assistants (psychol-
ogy students). Physicians from the Zurich University Hospital
of Psychiatry were involved in the procedure of blood sampling.
The gonadal hormones were exclusively derived from the blood
probes. However, no gonadal hormone assays were taken from
37 subjects. The reasons for this were participants refusing blood
sample collection or difficulties during blood sampling (e.g., prob-
lematic positions of veins). Of the 190 participants (men: n= 89;
women: n= 101) with complete hormone data, 137 subjects
(72.1%) were initially allocated to the stratum of high-scorers,
while 53 subjects (27.9%) were low scorers.
The ZInEP epidemiology survey study was approved by the
Ethical Committee of the canton of Zurich (KEK) and is in accor-
dance with the latest version of the Declaration of Helsinki. After
being extensively informed about study procedure and aims both
verbally and inwriting, the participants gave their written consent.
Measurements
Depressive Symptom Subtypes
Depressive symptom subtypes were assessed by a computer-
assisted version of the Structured Psychopathological Interview
and Rating of the Social Consequences of Psychological Distur-
bances for Epidemiology (SPIKE) used in the Zurich Study (38,
42). This instrument includes the most common psychopatho-
logical syndromes/disorders. The validity and reliability of the
SPIKE have been established for the assessment of depression and
anxiety (38). For the current study, we made use of the three
class solution, which had previously been extracted by a data-
driven technique (latent class analysis, LCA) from the SPIKE
data of 373 men manifesting depressive symptoms during the
past 12months (37): a melancholic depression subtype (n= 219;
58.7%), an atypical subtype (n= 64; 17.2%), and a moderate sub-
type (n= 90; 24.1%). We excluded the moderate subtype because
the investigation of the two clear discriminable melancholic and
atypical depression subtypes increased statistical power, which
was necessary due to the small sample sizes. The melancholic and
atypical depression subtypes are in line with previous subtyping
approaches and/or the DSM-5 specifiers (36, 43–47). The distinc-
tion of these two subtypes on the basis of appetite-/weight related
symptoms was particularly striking. Members of the atypical sub-
type showed high probabilities of increased appetite and weight
gain, whereas the melancholic subtype was characterized by loss
of appetite and weight. More detailed information about these
depressive subtypes and the entire LCA procedures can be found
elsewhere (37).
Overall, the T data were available for n= 89 men. From this
group, 39 subjects either matched with the melancholic or the
atypical depression subtype of the LCA three class solution (37).
A subgroup of 18 controls (defined without use of professional
help and low overall GSI-scores) was included. Consequently, the
present study was dealing with a sample of 57 subjects.
Psychosocial Characteristics
In order to characterize the depression subtypes, sociodemo-
graphic variables such as age, education, urbanicity, and mar-
ital status were drawn from the face-to-face interview. Axis I
diagnoses were computed according to DSM-III-R/IV criteria
for the time-period of the past 12months (48, 49). Only the
diagnosis of neurasthenia was derived from ICD-10 (50). Due to
methodological linkagewith the Zurich Study (38), the algorithms
of the DSM diagnoses were parallelized. As a consequence, some
diagnoses were based on an older edition of the DSM. Psychosis
syndromes were derived according to the algorithm of Rössler
et al. (40); bipolar disorder was derived in analogy to the BRIDGE
study (51). Personality disorders were assessed using the German
translation of the assessment of DSM-IV personality disorders
questionnaire (ADP-IV) (52, 53), showing good concordancewith
the SKID-II semi structured interview (54). The current smoking
status and the GSI were derived from the CATI. Finally, the data
concerning the consumption of psychiatricmedicationwere taken
from the laboratory day.
Biological Measures
Hormones
In order to ensure consistency due to diurnal variation (6) and in
accordance with the recommendation of an earlier study (55), the
blood sample was drawn in the morning. The exact time frame
of the blood sample collection lay between 08:55 a.m. and 10:34
a.m., 01:45–03:51 h after the subject’s awakening following an
overnight fast. Blood was centrifuged (10min; 3000 rpm) 30min
after the sample was taken and stored at  80°C until delivered to
the CYTOLAB for biochemical analysis. Total T was derived from
serum and measured by enzyme-linked immunosorbent assay
(ELISA) using a kit from IBL International, Hamburg, Germany.
Dehydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone
(LH), estradiol, and progesterone were also derived from serum.
While DHEA-S, estradiol, and progesterone were likewise assayed
by ELISA (DHEA-S: IBL International, Hamburg, Germany;
estradiol and progesterone: BioCheck, Foster City, USA), LH
was measured by Bead-Assay (Millipore, Zug, Switzerland). Sex
hormone-binding globulin (SHBG) was derived from ethylene
diamine tetraacetic acid (EDTA) plasma and measured by ELISA
using a kit from IBL International, Hamburg, Germany.
Blood pressure and BMI
Blood pressure was measured on the left upper arm in a sitting
position at the beginning of the laboratory assessment and 15min
later with the Boso Medicus Prestige (Bosch+ Sohn GmbH &
Co, KG DE). Both systolic and diastolic values were obtained and
averaged across the two measurements. BMI was conventionally
calculated, based on mass and height (kg/m2).
Statistical Analysis
All data were analyzed using SPSS version 20 for Macintosh (IBM
Corp., Armonk, NY, USA). The criterion for significance was set
at p< 0.05.
First, Chi2-tests and Fisher exact tests (two-tailed) and non-
parametric Kruskal–Wallis tests were performed in order to assess
differences of psychosocial characteristics between the depres-
sive subgroups atypical depression, melancholic depression, and
controls.
Second, unadjusted analyses of variance (ANOVAs) were per-
formed to evaluate the between-group differences on metric
dependent variables. Before performing the ANOVAs, Levene’s
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tests were computed in order to examine the homogeneity of
variances, and Shapiro–Wilk tests were used to account for the
assumption of normally distributed residuals. The values of Twere
log transformed (natural logarithm, ln) due to the non-normally
distributed residuals of the control group. In the ANOVAs, the
depressive subgroup served as independent variable and the bio-
logical characteristics were treated as the dependent variable.
Corresponding effect sizes were reported in terms of partial η2
[0.01= small, 0.06=medium, 0.14= large; (56)]. In case of sig-
nificant main effects, Scheffé and Games–Howell post hoc com-
parisons were used to explore all possible pairwise subgroup com-
parisons. Categorical biological characteristics were compared
between the subgroups with the Fisher’s exact test for categorical
variables (two-tailed). In addition, a non-parametric median test
was carried out on the T data. Finally, an analysis of covari-
ance (ANCOVA) considering the influence of the covariates age,
smoking, alcohol use, and psychopharmacological medication
was computed.
Third, the subgroup differences were further examined by gen-
eralized linear regression models (GLMs) using logistic regres-
sion. GLMs enable the use of robust estimators in order to min-
imize the effects of outliers and influential observations (57). T
was entered as independent variable and the subgroups served as
dependent variable.
Results
Psychosocial Characteristics
In Table 1, the psychosocial characteristics of the LCA-based
depressive subtypes and the control sample are displayed. No
significant differences in demographic correlates were observed
between these subsamples. However, groups differed with regard
to some comorbid 12-month diagnoses. As expected, both depres-
sive subtypes had higher frequencies of MDD diagnosis than the
controls. The severe atypical subtype revealed a diagnosis of gen-
eralized anxiety disorder (GAD) and simple phobia significantly
more often than the controls. In comparison with the melan-
cholic subtype, agoraphobia occurred significantly more often
in the atypical depression subtype. Atypical depression showed
significantly more psychosis syndromes and personality disor-
ders than the melancholic depression subtype and the controls.
Antidepressant consumption was significantly associated with the
atypical depression subtype (versus controls). Finally, in terms
of the subjectively rated burden related to health problems, both
depressive subtypes showed significantly higher values compared
with controls.
Biological Characteristics
The biological characteristics of the subsamples are summarized
in Table 2. The following T means and standard errors (SEs) (in
ng/ml) were observed: atypical subtype: 3.92 (0.37), melancholic
subtype 5.33 (0.28), and controls 4.87 (0.33). Log transformed data
were used for computing the ANOVA. The atypical depression
subtype differed significantly from the melancholic subtype with
regard to lower T levels. The differencewith respect to the controls
remained on a trend level of significance. The same subgroup
differences were found for SHBG. Furthermore, men manifest-
ing atypical depressive symptom configurations were significantly
more prone to a higher BMI than the melancholic depression
subgroup and controls, respectively. The corresponding effect
sizes of T, SHBG, and BMI were large.
In an extension of the analyses, the biological factors were cat-
egorized in order to validate the results in terms of medically rele-
vant cut-offs: hypogonadism, which was defined as <2.3 ng/mL
(58), occurred in n= 2 (14.3%) men belonging to the atypi-
cal depression subtype and the overall group differences could
only be expressed as trend level associations (χ2= 4.119, df= 2,
p= 0.06). The categorized BMI (normal weight: BMI 18.50–25.00;
overweight: BMI 25.01–30.00; obesity: 30.01) showed signifi-
cant overall differences (χ2= 12.435, df= 4, p< 0.05) with sig-
nificantly differing frequencies between the atypical depression
subtype [normalweight: n= 5 (38.5%); overweight: n= 4 (30.8%);
obesity: n= 4 (30.8%)] and the melancholic depression subtype
[normal weight: n= 21 (84.0%); overweight: n= 4 (16.0%); obe-
sity: n= 0 (0.0%)], and controls [normal weight: n= 13 (72.2%);
overweight: n= 5 (26.8%); obesity: n= 0 (0.0%)], respectively.
The categorized blood pressure revealed no single cases of
hypotension (defined as <90/60mmHg). In contrast, hyperten-
sion (defined as >140/90mmHg) occurred most frequently in
the melancholic depression subtype (n= 8; 72.7%). However, the
overall differences failed to achieve a customary level of statistical
significance (χ2= 4.539, df= 2, p= 0.107) (data not tabulated).
The non-parametric median test provided significant overall
subgroup differences regarding the T levels (χ2= 6.685, df= 2,
p< 0.05). An additional ANCOVA, adjusted for the influence of
age, smoking, alcohol use, and psychopharmacological medica-
tion, showed comparable results (F= 3.472, df= 2, p< 0.05). The
BMI was neither included in the ANCOVA nor the following
adjusted models because it showed high multicollinearity with
the atypical depressive subtype and T, respectively. The adjusted
means and SEs are visualized in Figure 2.
Generalized linear regression models were carried out by con-
trasting the three subgroups, while adjusting for age, smoking,
alcohol use, and psychopharmacological medication. The analysis
contrasting the atypical depression subgroupwith themelancholic
subgroup and controls, respectively, showed significant odds
ratios (OR) between atypical and melancholic (reference) depres-
sion [OR= 0.024, 95% confidence intervals (CI): 0.001–0.640,
p< 0.05] with lower T levels in the atypical subgroup. Apart
from a trend-level association, T levels did not significantly differ
between atypical depression and controls (reference) (OR= 0.103,
CI: 0.007–1.576, p= 0.10). No significant difference was found
between the T levels of the melancholic depressives and controls
(reference) (OR= 2.806, CI: 0.190–41.375, p= 0.45) (data not
tabulated).
Discussion
This is a preliminary study examining differences of serum T
levels in empirically derived symptom-based depression subtypes
and a healthy control group in a Swiss community sample of male
adults. The results provided evidence that the atypical depression
subtype is discriminable by low serum T levels in men aged
between 21 and 41. First, our results support the notion that
the inconsistent evidence from previous studies with respect to
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TABLE 1 | Psychosocial characteristics for men belonging to the depressive subtypes derived from latent class analyses (n=39) and healthy controls
(n=18), unadjusted.
Characteristica Atypical MDD Melancholic MDD Controls p-value
n= 14 n= 25 n= 18
Chi2/F-test (two-tailed, overall; post hoc tests
comparing each subtype separately with all others)
Age 0.957
21 4 (28:6) 3 (12:0) 3 (16:7)
23 2 (14:3) 4 (16:0) 2 (11:1)
28 3 (21:4) 6 (24:0) 5 (27:8)
30 2 (14:3) 4 (16:0) 2 (11:1)
35 2 (14:3) 2 (8:0) 3 (16:7)
41 1 (7:1) 6 (24:0) 3 (16:7)
Educationb, n (%) 0:211
Low 11 (78:6) 16 (64:0) 8 (47:1)
High 3 (21:4) 9 (36:0) 9 (52:9)
Urbanicityc, n (%) 0:222
Urban 13 (92:9) 19 (76:0) 12 (66:7)
Rural 1 (7:1) 6 (24:0) 6 (33:3)
Marital status, n (%) 0:608
Unmarried 9 (64:3) 19 (76:0) 14 (77:8)
Married 4 (28:6) 6 (24:0) 4 (22:2)
Divorced 1 (7:1) 0 (0:0) 0 (0:0)
Comorbiditiesd (past year) n (%)
MDDe 6 (42:9) 13 (52:0) 0 (0:0) <0:001r, s
Dysthymiae 2 (14:3) 2 (8:0) 0 (0:0) 0:267
Hypomania/maniaf 3 (21:4) 4 (16:0) 0 (0:0) 0:105
Bipolar disorderg 3 (21:4) 2 (8:0) 0 (0:0) 0:111
Neurastheniah, i 1 (7:1) 6 (27:3) 1 (5:6) 0:144
GADj 5 (35:7) 2 (8:0) 0 (0:0) <0:01r
Simple phobiaf 5 (41:7) 4 (19:0) 0 (0:0) <0:05r
Social phobiaf 3 (21:4) 5 (23:8) 0 (0:0) 0:061
Agoraphobiaf 3 (21:4) 0 (0:0) 0 (0:0) <0:05q
Psychosis syndromesk 5 (35:7) 1 (4:0) 0 (0:0) <0:01q, r
Panic disorderf 1 (8:3) 2 (8:3) 0 (0:0) 0:443
OCDf 1 (7:1) 1 (4:0) 0 (0:0) 0:718
Binge eatingf, l 4 (28:6) 2 (8:0) 1 (5:6) 0:144
Anorexia nervosae 0 (0:0) 1 (4:0) 0 (0:0) n/a
Suicide attempt 1 (10:0) 1 (5:9) 0 (0:0) 0:695
Alcohol dependencef 2 (14:3) 4 (16:0) 0 (0:0) 0:214
Alcohol abusef 1 (7:1) 1 (4:0) 0 (0:0) 0:718
Current smoking 4 (28:6) 11 (44:0) 5 (27:8) 0:525
Any personality disorderm 4 (28:6) 1 (4:0) 0 (0:0) <0:05q, r
Psychopharmaceuticals, nn 4 (30:8) 4 (23:5) 0 (0:0) 0:776
Antidepressant 4 (28:6) 2 (8:0) 0 (0:0) <0:05r
Mood stabilizer 1 (7:1) 1 (4:0) 0 (0:0) 0:718
Sedative, hypnotic, anxiolytic 1 (7:1) 0 (0:0) 0 (0:0) 0:246
Neuroleptics 1 (7:1) 0 (0:0) 0 (0:0) 0:246
Other 1 (7:1) 1 (4:0) 0 (0:0) 0:718
Subjective impairment (meanSE)o Kruskal–Wallis testp
GSI 2:25 (0:16) 2:17 (0:07) 1:34 (0:06) <0:001r, s
MDD, major depressive disorder; DYST, dysthymia; GAD, generalized anxiety disorder; OCD, obsessive–compulsive disorder; n/a, not available.
aThe discrepancy between the total number of persons and the number of persons in the following rows result from missing items.
bAlthough the Swiss educational degrees do not entirely correspond with the school system of Anglo-American areas or other countries, the educational degrees were comparatively
grouped into the two following categories: low, less than high school diploma; high, high school diploma or higher.
cUrban: Zurich, Winterthur; rural: remaining municipalities of the canton of Zurich.
d12-month prevalence.
eDSM-III-R.
fDSM-IV.
gDef. BRIDGE study (51).
h ICD-10.
i3-month criteria.
jDSM-III.
kDisorders of form of thought, derealization, depersonalization, delusion, disorder of ego-boundary, hallucinations, paranoia syndrome.
l Including binge eating symptoms.
mParanoid, schizotypal, avoidant, dependent, obsessive–compulsive, borderline, histrionic, narcissistic, and depressive.
nConsumption of psychopharmaceuticals during the past 6months.
oGlobal severity index (GSI) of the SCL-27 (41).
pPost hoc tests: pairwise Kruskal–Wallis tests.
qAtypical MDD significantly differs from melancholic MDD.
rAtypical MDD significantly differs from controls.
sMelancholic MDD significantly differs from controls.
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TABLE 2 | Biological characteristics of men belonging to the depressive subtypes derived from latent class analyses (n=39) and healthy controls (n=18),
unadjusted.
Biological characteristics Atypical MDD Melancholic MDD Controls
n= 14 n= 25 n= 18
Mean (SE) Mean (SE) Mean (SE) Eta (η2) p-valuea
Testosterone (ln) 1:32 (0:08) 1:64 (0:06) 1:54 (0:07) 0.17 0:01e, (f)
SHBG (nmol/L)b 26:10 (4:29) 42:04 (2:71) 40:44 (4:52) 0.20 0:01e, (f)
DHEA-S (ug/mL) 2:17 (0:81) 2:48 (0:69) 2:31 (0:98) 0.02 0:513
LH (mlU/ml)c 2:59 (0:56) 3:18 (0:37) 2:80 (0:61) 0.02 0:653
Estradiol (ng/mL) 28:18 (2:10) 26:32 (1:57) 26:72 (1:85) 0.01 0:774
Progesterone (ng/mL) 0:87 (0:14) 1:01 (0:11) 0:92 (0:13) 0.01 0:713
BMId 29:03 (0:92) 23:43 (0:67) 23:06 (0:78) 0.36 0:001e, f
Diastolic BP (mmHg)d 88:58 (2:98) 86:04 (2:15) 82:75 (2:53) 0.04 0:324
Systolic BP (mmHg)d 133:23 (3:51) 133:10 (2:53) 128:94 (2:99) 0.02 0:515
MDD, major depressive disorder; ANOVA, analysis of variance; SHBG, sex hormone-binding globulin; DHEA-S, dehydroepiandrosterone-sulfate; LH, luteinizing hormone; BMI, body
mass index; BP, blood pressure.
aOne-way ANOVA/post hoc tests: Scheffé (homogeneous variances), Games–Howell (non-homogeneous variances).
bMissing data: atypical MDD, n=4; controls, n=9.
cMissing data: atypical MDD, n=3; controls, n=9.
dMissing data: atypical MDD, n=1.
eAtypical MDD significantly differs from melancholic MDD.
fAtypical MDD significantly differs from controls
(f)Parenthesis indicating trend-level associations p0.12.
FIGURE 2 | Comparison of mean (SE) log transformed (natural logs, ln) serum testosterone levels between the depressive subtypes and healthy
controls after adjustment for age, smoking, alcohol abuse, and psychopharmacological medication.
T levels and MDD may have resulted from the heterogeneity
of this diagnosis, while the investigation of more homogeneous
symptom-based subtypes provides a more detailed picture. Sec-
ond, the current analyses confirmed previous findings showing
that the melancholic and atypical depressive subtypes were dis-
tinguishable by biological correlates (29, 31), and expanded this
knowledge via the aspect of gonadal hormones.
Our results suggest that the previous findings of low T levels in
depressedmen (4, 6, 8–10)might have resulted from the subgroup
of atypical depressives. In fact, the “irritable male syndrome,” a
behavioral state following withdrawal of T in adult male mam-
mals (21), shows a certain similarity to the symptoms of atypical
depression (30) in human adults. There are several explanations
for this specific biological correlate within atypical depressives.
The low T levels in atypical depressives could be explained by
the high BMI associated with this subtype; this marked biologi-
cal characteristic of atypical depression will be discussed further
below. A further conceivable analogy can be drawn from studies
demonstrating differences inHPA axis regulation betweenmelan-
cholic and atypical depression (31, 59). Melancholic depression
was characterized by hypercortisolism while atypical depression
was associatedwith hypocortisolism (31). In combinationwith the
evidence concerning the interactive nature in which the HPA and
the HPG axes operate (33) this opens up interesting perspectives.
A fairly recent community study on a sample of men showed a
positive correlation between endogenous evening saliva T and
overall depression scores, as well as evening cortisol (HPA axis)
(34, 60). This relation was explained by the effect of cortisol
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modifying the gonadotropin-releasing hormone (GnRH) from
the hypothalamus, by influencing the LH from the pituitary or by
alterations in the stimulating effect of gonadotropins or gonads
(34, 61). To return to the depression subtypes, it thus appears
plausible that the down-regulated HPA axis is correlated with low
T levels, or even hypogonadism, in atypical depressives. Also,
SHBG, which is correlated with T (35), was significantly lower
in the atypical depression subtype compared with the melan-
cholic subtype. In line with this hypothesis, the hypercortisolism-
associated melancholic subtype should show the opposite, namely
T level alterations.
The initially expected higher T levels in themelancholic depres-
sion subtype were based on the available literature concerning
the HPA axis dysregulation of this subtype (31) and exogenous
T administration demonstrating that a high T dose resulted in
both depression and hypomania/mania (24–28). In our study, T
levels were actually higher in the melancholic depression subtype
compared to both other groups, although they only differed sig-
nificantly from the atypical group. Therefore, our two depression
subtypes were found at both the lowest and highest areas of T
distribution, which would be in line with the parabolic model
displaying a curvilinear relationship between T and depression
(13, 15, 22). However, considering the fact that the T levels of the
melancholic subtype were similar to the controls and, moreover,
far from significantly differing from the latter (whereas the atypi-
cal depression subtype did at least on a trend-level), the clinical
relevance of the elevated T levels in the current study can be
questioned. Further studies are needed to replicate the findings of
diverging T levels between melancholic and atypical depression
with larger sample sizes.
Beyond the gonadal hormone T characterizing the atypical
depression subtype, the effect size was particularly striking for
BMI. In fact, it was more than twice as large as that of T. This
is in line with previous findings (29, 36) demonstrating a positive
association between BMI and atypical depression. A prospective,
population-based study revealed that atypical depression was a
strong predictor of obesity with an OR of 3.75 (62). Therefore, the
BMI seems to be a constitutive characteristic of atypical depres-
sion. In the current analysis, however, the simultaneous investiga-
tion of T and BMI was not possible due to inherent model-based
constraints combined with the small sample size. Further studies
should determine if the low T levels of the atypical depressive
subtype are simply an epiphenomenon of the high BMI associated
with this subtype. Moreover, all biological systems/markers (e.g.,
HPA axis, HPG axis, metabolic abnormalities such as obesity,
and inflammatory markers) associated with atypical depression
should be balanced in their clinical relevance and better examined
with regard to their possible interactions.
Taken together, the atypical depression subtype once again
appeared diametrically opposed to the remaining subjects. Apart
from its discriminable symptom- and comorbidity profile it also
showed specific biological correlates in the current sample of
men. It is remarkable that men belonging to the atypical subtype
not only exhibited lower T levels but also, moreover, showed a
comorbidity profile usually found in depressive women, that is to
say phobias and anxiety. Further studies should show whether our
speculation re a feminine profile in atypical depressivemen can be
confirmed.
Some studies reported a relationship between low T levels and
subthreshold depressive disorders (15, 17, 20). One epidemiolog-
ical study reported that lower T levels are only associated with
subthreshold symptoms of anxiety and depression (19). Anxiety
symptoms were not included as LCA indicators when deriving
the depressive subtypes (37) and the moderate subtype including
subjects with a lower severity of depression was excluded from
the current analysis in order to increase statistical power. Con-
sequently, we could not further examine this issue. However, an
exploratory analysis did not indicate any deviation of the T levels
in the moderate depression subgroup.
The following limitations should be noted. First, the sample
sizes of the examined subsamples were small and only strong
effects achieve common significance levels with small sample
sizes. Although we applied robust statistical methods and addi-
tionally computed effect sizes, replications of our findings with
representative, large samples are necessary. Second, we cannot
draw causal conclusions from our data due to the cross-sectional
design. The contradictory evidence with regard to causality of
the differing T levels and affective symptoms (15, 63) needs fur-
ther investigation. Hence, the current performance of regression
analytic methods implying a causal direction needs to be inter-
preted as preliminary. Future studies are required to replicate our
findings, to longitudinally analyze causal processes [particularly
with regard to the interaction between HPG and HPA axes due
to their great therapeutic and diagnostic potential (33)], and to
assess a broader age range in order to more precisely consider the
possibility of age-specific features (64–66). Third, the participants
of the laboratory day were selected as a convenience sample.
Consequently, a certain selection bias and a restricted external
validity cannot be completely excluded. Fourth, we draw analogies
between the effects of exogenous high dose T with endogenous
serum T values although we can not ensure that there is a direct
correlation between these biological markers. Fifth, as Jäger et al.
(67) emphasized, the comparison of studies examining the issue
of T deficiency is difficult because there is no international con-
sensus on the definition of a standardized normal range of hypog-
onadism. Sixth, the calculation of free testosterone using total T
and SHGB (68) could be added in future research.
Despite these limitations and its preliminary nature, this com-
munity study demonstrated for the first time lower serum T levels
of the empirically derived atypical depression subtype in men.
If the current biological findings would be replicated in larger
samples, this additional differentiation of depressive subtypes
by biological features may indicate distinctive pathophysiolog-
ical entities and could ameliorate the specificity of depression
diagnoses and treatments.
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